Amundi Has $1.69 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Amundi raised its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,309 shares of the company's stock after buying an additional 14,115 shares during the period. Amundi owned approximately 0.08% of Omnicell worth $1,694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. raised its holdings in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company's stock worth $12,820,000 after buying an additional 259,463 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock valued at $49,742,000 after buying an additional 243,353 shares during the period. Finally, Pier Capital LLC bought a new position in Omnicell during the third quarter valued at about $5,859,000. 97.70% of the stock is currently owned by institutional investors.

Remove Ads

Omnicell Stock Down 2.7 %

NASDAQ:OMCL traded down $0.94 on Friday, hitting $33.94. 1,836,421 shares of the company's stock traded hands, compared to its average volume of 498,790. The firm has a 50-day moving average price of $39.94 and a 200-day moving average price of $42.98. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.59 billion, a PE ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

OMCL has been the subject of a number of research analyst reports. Benchmark reissued a "buy" rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Bank of America reduced their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th. Finally, JPMorgan Chase & Co. decreased their price target on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of "Hold" and a consensus price target of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.